Clearmind Medicine Initiates Phase IIa Trial for CMND-100 in AUD Treatment

Vancouver, Canada, Sept. 01, 2026 /CourierPR/ -- Clearmind Medicine Inc., a clinical-stage biopharmaceutical company based in the United States, has reached a significant milestone in its ongoing research for alcohol use disorder (AUD). The company announced the initiation of Phase IIa, the next phase of its double-blind, placebo-controlled Phase I/IIa clinical trial evaluating CMND-100, a non-hallucinogenic psychedelic-derived neuroplastogen, for the treatment of AUD. So far, six patients have been enrolled in the trial, with three participants each from Tel Aviv Sourasky Medical Center and Hadassah Medical Center in Jerusalem.

This latest phase of the clinical trial is designed to evaluate the safety, tolerability, and preliminary efficacy of CMND-100 in individuals with moderate-to-severe AUD. The study is structured as a four-part Phase I/IIa study, which includes a single and multiple dose tolerability, safety, and pharmacokinetic study in both healthy volunteers and individuals with AUD.

CMND-100 is Clearmind's lead investigational psychedelic-based therapeutic candidate. The company is developing it as a potential treatment for AUD, a chronic condition characterized by an impaired ability to stop or control alcohol consumption despite significant social, occupational, or health consequences. AUD remains a major global health burden, with substantial unmet medical needs and limited effective treatment options.

The company previously reported that an independent Data and Safety Monitoring Board (DSMB) reviewed clinical data generated during the initial safety part of the trial and recommended advancing to the subsequent parts of the study. This positive DSMB assessment supports the continued clinical evaluation of CMND-100 and the simultaneous progression of the program into multiple dosing in healthy volunteers and single dosing in AUD patients.

Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of non-hallucinogenic, next-generation, psychedelic-derived neuroplastogens for the scalable treatment of neuropsychiatric, metabolic, and addiction disorders, including AUD. The company's intellectual portfolio currently includes 19 patent families, with 32 granted patents. Its primary objective is to research and develop psychedelic-based compounds and potentially commercialize them as regulated medicines, foods, or supplements. Clearmind continues to seek additional patents for its compounds whenever warranted and remains opportunistic regarding the acquisition of additional intellectual property to build its portfolio.